{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T03:30:20Z","timestamp":1784086220539,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:00:00Z","timestamp":1567123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:00:00Z","timestamp":1567123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s11886-019-1198-5","type":"journal-article","created":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T09:03:27Z","timestamp":1567155807000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios"],"prefix":"10.1007","volume":"21","author":[{"given":"Graham R.","family":"McClure","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Kaplovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukrit","family":"Narula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinai C.","family":"Bhagirath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia S.","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,30]]},"reference":[{"issue":"9901","key":"1198_CR1","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","volume":"382","author":"FGR Fowkes","year":"2013","unstructured":"Fowkes FGR, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382(9901):1329\u201340. \n                      https:\/\/doi.org\/10.1016\/S0140-6736(13)61249-0\n                      \n                    .","journal-title":"Lancet."},{"issue":"9","key":"1198_CR2","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1161\/CIRCRESAHA.116.303849","volume":"116","author":"MH Criqui","year":"2015","unstructured":"Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015;116(9):1509\u201326. \n                      https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.303849\n                      \n                    .","journal-title":"Circ Res"},{"issue":"20","key":"1198_CR3","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1016\/j.jacc.2018.03.008","volume":"71","author":"SS Anand","year":"2018","unstructured":"\u2022 Anand SS, Caron F, Eikelboom JW, et al. Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS Trial. J Am Coll Cardiol. 2018;71(20):2306\u201315. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2018.03.008\n                      \n                     Findings from this analysis of the COMPASS trial highlight the predictors of MALE, the adverse prognosis after MALE in terms of the increased risk of vascular amputation, re-hospitalization, MACE, and death.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"1198_CR4","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1016\/j.jacc.2018.08.002","volume":"72","author":"N Narula","year":"2018","unstructured":"Narula N, Dannenberg AJ, Olin JW, et al. Pathology of peripheral artery disease in patients with critical limb ischemia. J Am Coll Cardiol. 2018;72(18):2152\u201363. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2018.08.002\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"1198_CR5","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","volume":"377","author":"John W. Eikelboom","year":"2017","unstructured":"Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. August 2017. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1709118\n                      \n                    .","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"1198_CR6","doi-asserted-by":"publisher","first-page":"e686","DOI":"10.1161\/CIR.0000000000000470","volume":"135","author":"MD Gerhard-Herman","year":"2017","unstructured":"Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135(12):e686\u2013725. \n                      https:\/\/doi.org\/10.1161\/CIR.0000000000000470\n                      \n                    .","journal-title":"Circulation."},{"issue":"2","key":"1198_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1177\/1358863X18820123","volume":"24","author":"E Kaplovitch","year":"2019","unstructured":"Kaplovitch E, Rannelli L, Anand SS. Antithrombotics in stable peripheral artery disease. Vasc Med Lond Engl. 2019;24(2):132\u201340. \n                      https:\/\/doi.org\/10.1177\/1358863X18820123\n                      \n                    .","journal-title":"Vasc Med Lond Engl"},{"issue":"12","key":"1198_CR8","first-page":"997","volume":"21","author":"BL Abramson","year":"2005","unstructured":"Abramson BL, Huckell V, Anand S, et al. Canadian Cardiovascular Society Consensus Conference: peripheral arterial disease-executive summary. Can J Cardiol. 2005;21(12):997\u20131006.","journal-title":"Can J Cardiol"},{"issue":"9","key":"1198_CR9","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"Victor Aboyans","year":"2017","unstructured":"Aboyans V, Ricco J-B, Bartelink M-LEL, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763\u2013816. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/ehx095","journal-title":"European Heart Journal"},{"issue":"18","key":"1198_CR10","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1001\/jama.2009.623","volume":"301","author":"JS Berger","year":"2009","unstructured":"Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA. 2009;301(18):1909\u201319. \n                      https:\/\/doi.org\/10.1001\/jama.2009.623\n                      \n                    .","journal-title":"JAMA."},{"key":"1198_CR11","doi-asserted-by":"publisher","unstructured":"Wong PF, Chong LY, Mikhailidis DP, Robless P, Stansby G. Antiplatelet agents for intermittent claudication. Cochrane Database Syst Rev. 2011;(11):CD001272. \n                      https:\/\/doi.org\/10.1002\/14651858.CD001272.pub2\n                      \n                    .","DOI":"10.1002\/14651858.CD001272.pub2"},{"issue":"9038","key":"1198_CR12","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"CAPRIE Steering Committee","year":"1996","unstructured":"CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet Lond Engl. 1996;348(9038):1329\u201339.","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"1198_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1611688","volume":"376","author":"WR Hiatt","year":"2017","unstructured":"Hiatt WR, Fowkes FGR, Heizer G, et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2017;376(1):32\u201340. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1611688\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"2","key":"1198_CR14","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/eurheartj\/ehn534","volume":"30","author":"PP Cacoub","year":"2009","unstructured":"Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA, CHARISMA Investigators. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009;30(2):192\u2013201. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/ehn534\n                      \n                    .","journal-title":"Eur Heart J"},{"issue":"19","key":"1198_CR15","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","volume":"49","author":"DL Bhatt","year":"2007","unstructured":"Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49(19):1982\u20138. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2007.03.025\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"1198_CR16","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","volume":"366","author":"DA Morrow","year":"2012","unstructured":"Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366(15):1404\u201313. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1200933\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"20","key":"1198_CR17","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1016\/j.jcin.2016.07.034","volume":"9","author":"MP Bonaca","year":"2016","unstructured":"Bonaca MP, Creager MA, Olin J, et al. Peripheral revascularization in patients with peripheral artery disease with vorapaxar: insights from the TRA 2\u00b0P-TIMI 50 Trial. JACC Cardiovasc Interv. 2016;9(20):2157\u201364. \n                      https:\/\/doi.org\/10.1016\/j.jcin.2016.07.034\n                      \n                    .","journal-title":"JACC Cardiovasc Interv"},{"key":"1198_CR18","doi-asserted-by":"publisher","unstructured":"\u2022 Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007;357(3):217\u2013227. \n                      https:\/\/doi.org\/10.1056\/NEJMoa065959\n                      \n                    . This paper shows the results of the warfarin antiplatelet vascular evaluation (WAVE) trial which resulted in no ischemic reduction in PAD patients treated with moderate-intensity warfarin and antiplatelet therapy and a significant increase in life-threatening bleeding with this combination.","DOI":"10.1056\/NEJMoa065959"},{"issue":"9201","key":"1198_CR19","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S0140-6736(99)07199-8","volume":"355","author":"Efficacy of oral anticoagulants","year":"2000","unstructured":"Efficacy of oral anticoagulants. compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. Lancet Lond Engl. 2000;355(9201):346\u201351.","journal-title":"Lancet Lond Engl"},{"issue":"12","key":"1198_CR20","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351. \n                      https:\/\/doi.org\/10.1056\/NEJMoa0905561\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"2","key":"1198_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","volume":"149","author":"C Kearon","year":"2016","unstructured":"Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. CHEST. 2016;149(2):315\u201352. \n                      https:\/\/doi.org\/10.1016\/j.chest.2015.11.026\n                      \n                    .","journal-title":"CHEST."},{"issue":"1","key":"1198_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"JL Mega","year":"2012","unstructured":"Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9\u201319. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1112277\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"10117","key":"1198_CR23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","volume":"391","author":"Sonia S Anand","year":"2018","unstructured":"\u2022 Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet Lond Engl. 2017. \n                      https:\/\/doi.org\/10.1016\/S0140-6736(17)32409-1\n                      \n                     This is the main result of the COMPASS PAD subgroup from the COMPASS trial showing the significant 31% relative risk reduction in major adverse cardiovascular events or major adverse limb events with the low-dose rivaroxaban and aspirin combination over aspirin only.","journal-title":"The Lancet"},{"issue":"9","key":"1198_CR24","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1093\/eurheartj\/ehx658","volume":"39","author":"A Darmon","year":"2018","unstructured":"Darmon A, Bhatt DL, Elbez Y, et al. External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. Eur Heart J. 2018;39(9):750\u2013757a. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/ehx658\n                      \n                    .","journal-title":"Eur Heart J"},{"issue":"25","key":"1198_CR25","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1016\/j.jacc.2019.02.079","volume":"73","author":"SS Anand","year":"2019","unstructured":"\u2022 Anand SS, Eikelboon JW, Dyal L, et al. Impact of rivaroxaban plus aspirin compared with aspirin by risk level in the COMPASS trial. 2019. J Am Coll Cardiol. 2019;73(25):3271\u201380. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2019.02.079\n                      \n                     This risk stratification analysis highlights the higher absolute risk reduction in subgroups of patients from the COMPASS trial when treated with low-dose rivaroxaban and aspirin compared to aspirin alone. The highest risk groups are patients with 2 or more vascular beds affected, renal insufficiency, history of heart failure, and diabetes.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"1198_CR26","doi-asserted-by":"publisher","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","volume":"146","author":"RG Hart","year":"2007","unstructured":"Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857\u201367.","journal-title":"Ann Intern Med"},{"key":"1198_CR27","unstructured":"Xarelto Product Monograph. \n                      https:\/\/www.bayer.ca\/omr\/online\/xarelto-pm-en.pdf\n                      \n                    ."},{"issue":"1","key":"1198_CR28","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s11239-015-1310-7","volume":"41","author":"AE Burnett","year":"2016","unstructured":"Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. 2016;41(1):206\u201332. \n                      https:\/\/doi.org\/10.1007\/s11239-015-1310-7\n                      \n                    .","journal-title":"J Thromb Thrombolysis"},{"issue":"16","key":"1198_CR29","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.jacc.2007.11.077","volume":"51","author":"GMJM Welten","year":"2008","unstructured":"Welten GMJM, Schouten O, Hoeks SE, et al. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J Am Coll Cardiol. 2008;51(16):1588\u201396. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2007.11.077\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1198_CR30","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1001\/jamasurg.2016.0415","volume":"151","author":"MA Hussain","year":"2016","unstructured":"Hussain MA, Al-Omran M, Mamdani M, et al. Efficacy of a guideline-recommended risk-reduction program to improve cardiovascular and limb outcomes in patients with peripheral arterial disease. JAMA Surg. 2016;151(8):742\u201350. \n                      https:\/\/doi.org\/10.1001\/jamasurg.2016.0415\n                      \n                    .","journal-title":"JAMA Surg"},{"issue":"2","key":"1198_CR31","doi-asserted-by":"publisher","first-page":"e000697","DOI":"10.1161\/JAHA.113.000697","volume":"3","author":"EJ Armstrong","year":"2014","unstructured":"Armstrong EJ, Chen DC, Westin GG, et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc. 2014;3(2):e000697. \n                      https:\/\/doi.org\/10.1161\/JAHA.113.000697\n                      \n                    .","journal-title":"J Am Heart Assoc"},{"key":"1198_CR32","unstructured":"Lamy A. Costs impact rivaroxaban plus aspirin versus aspirin in the COMPASS trial. Presented at the: 2017 American Heart Association Scientific Sessions; November 11, 2017."},{"key":"1198_CR33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ahj.2018.01.011","volume":"199","author":"WH Capell","year":"2018","unstructured":"Capell WH, Bonaca MP, Nehler MR, et al. Rationale and design for the vascular outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). Am Heart J. 2018;199:83\u201391. \n                      https:\/\/doi.org\/10.1016\/j.ahj.2018.01.011\n                      \n                    .","journal-title":"Am Heart J"},{"key":"1198_CR34","doi-asserted-by":"crossref","unstructured":"Levine Glenn N., Bates Eric R., Bittl John A., et al. 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention, 2011 ACCF\/AHA guideline for coronary artery bypass graft surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA\/ACC guideline for the management of patients with non\u2013ST-elevation acute coronary syndromes, and 2014 ACC\/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134(10):e123-e155. doi:10.1161\/CIR.0000000000000404","DOI":"10.1161\/CIR.0000000000000404"},{"issue":"11","key":"1198_CR35","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045\u201357. \n                      https:\/\/doi.org\/10.1056\/NEJMoa0904327\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"10117","key":"1198_CR36","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0140-6736(17)32458-3","volume":"391","author":"SJ Connolly","year":"2018","unstructured":"Connolly SJ, Eikelboom JW, Bosch J, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet Lond Engl. 2018;391(10117):205\u201318. \n                      https:\/\/doi.org\/10.1016\/S0140-6736(17)32458-3\n                      \n                    .","journal-title":"Lancet Lond Engl"},{"issue":"19","key":"1198_CR37","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","volume":"372","author":"MP Bonaca","year":"2015","unstructured":"Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791\u2013800. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1500857\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"23","key":"1198_CR38","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","volume":"67","author":"MP Bonaca","year":"2016","unstructured":"Bonaca MP, Bhatt DL, Storey RF, et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol. 2016;67(23):2719\u201328. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2016.03.524\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"1198_CR39","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.amjcard.2007.06.034","volume":"100","author":"MD Ezekowitz","year":"2007","unstructured":"Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007;100(9):1419\u201326. \n                      https:\/\/doi.org\/10.1016\/j.amjcard.2007.06.034\n                      \n                    .","journal-title":"Am J Cardiol"},{"issue":"9","key":"1198_CR40","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1007\/s00330-012-2441-2","volume":"22","author":"G Tepe","year":"2012","unstructured":"Tepe G, Bantleon R, Brechtel K, et al. Management of peripheral arterial interventions with mono or dual antiplatelet therapy\u2014the MIRROR study: a randomised and double-blinded clinical trial. Eur Radiol. 2012;22(9):1998\u20132006. \n                      https:\/\/doi.org\/10.1007\/s00330-012-2441-2\n                      \n                    .","journal-title":"Eur Radiol"},{"issue":"2","key":"1198_CR41","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1177\/1526602818760488","volume":"25","author":"F Moll","year":"2018","unstructured":"Moll F, Baumgartner I, Jaff M, et al. Edoxaban plus aspirin vs dual antiplatelet therapy in endovascular treatment of patients with peripheral artery disease: results of the ePAD trial. J Endovasc Ther Off J Int Soc Endovasc Spec. 2018;25(2):158\u201368. \n                      https:\/\/doi.org\/10.1177\/1526602818760488\n                      \n                    .","journal-title":"J Endovasc Ther Off J Int Soc Endovasc Spec"},{"issue":"1","key":"1198_CR42","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1365-2125.2012.04181.x","volume":"74","author":"XS Xu","year":"2012","unstructured":"Xu XS, Moore K, Burton P, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. Br J Clin Pharmacol. 2012;74(1):86\u201397. \n                      https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04181.x\n                      \n                    .","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"1198_CR43","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","volume":"61","author":"D Kubitza","year":"2005","unstructured":"Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939\u2014an oral, direct Factor Xa inhibitor\u2014after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61(12):873\u201380. \n                      https:\/\/doi.org\/10.1007\/s00228-005-0043-5\n                      \n                    .","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1198-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-019-1198-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1198-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T23:48:07Z","timestamp":1598658487000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-019-1198-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,30]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["1198"],"URL":"https:\/\/doi.org\/10.1007\/s11886-019-1198-5","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,30]]},"assertion":[{"value":"30 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Graham R. McClure, Eric Kaplovitch, and Sukrit Narula declare that they have no conflict of interest.Vinai C. Bhagirath reports grants and personal fees from Pfizer, and personal fees from Bayer.Sonia S. Anand reports grants and personal fees from Bayer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"115"}}